Myriad Genetics Posts 21 Percent Revenue Growth for Q1 2013

Nov 06, 2012

|

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Monday that its Fiscal Year 2013 first-quarter revenues increased 21 percent year over year.

The firm also upped its revenue and profit guidance for the year.

The Salt Lake City-based molecular diagnostics firm reported total revenues of $133.4 million for the three months ended Sept. 30, compared to $110.5 million for the first quarter of FY 2012. It beat analysts' consensus estimate of $129.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Main menu